CCB Safety Study in Treatment of Hypertension of ADPKD

Kidney, Polycystic, Autosomal Dominant Clinical Trial

Official title: Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients

Status Unknown status

Clinical Trial Summary

This study examines the safety and efficacy of calcium channel blocker (CCB) in the treatment of hypertension of Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients. Angiotensin receptor blocker (ARB) was shown to have kidney protecting effects in patients with renal diseases including ADPKD, glomerulonephritis and diabetic nephropathy. In case whose blood pressure is not normalized by ARB alone, CCB is selected additionally. Recent research suggests genetic calcium channel disorder is responsible for the progression of ADPKD. It is not examined clinically if CCB treatment has any harmful effect to patients with ADPKD. This study examines the safety of Cilnidipine (CCB) in the ADPKD patients whose blood pressure is not controlled under 130/85 mmHg by Candesartan (ARB) alone.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Kidney, Polycystic, Autosomal Dominant
• Polycystic Kidney Diseases
• Polycystic Kidney, Autosomal Dominant

• NCT number: NCT00541853
• Study type: Interventional
• Source: Kyorin University
• Contact: Eiji Higashihara, M.D.
• Phone: +81-422-47-5511
• Email: ehigashi@kyorin-u.ac.jp
• Status: Unknown status
• Phase: Phase 4
• Start date: December 2007
• Completion date: November 2012